150 related articles for article (PubMed ID: 25416438)
1. LAPTM4B-35 protein as a potential therapeutic target in gastric cancer.
Zhang H; Tian B; Yu H; Yao H; Gao Z
Tumour Biol; 2014 Dec; 35(12):12737-42. PubMed ID: 25416438
[TBL] [Abstract][Full Text] [Related]
2. LAPTM4B-35, a cancer-related gene, is associated with poor prognosis in TNM stages I-III gastric cancer patients.
Cheng X; Zheng Z; Bu Z; Wu X; Zhang L; Xing X; Wang X; Hu Y; Du H; Li L; Li S; Zhou R; Wen XZ; Ji JF
PLoS One; 2015; 10(4):e0121559. PubMed ID: 25849595
[TBL] [Abstract][Full Text] [Related]
3. Lysosomal-associated protein transmembrane 4 Beta-35 overexpression is a novel independent prognostic marker for gastric carcinoma.
Liu L; Xu X; Jing L; Zhou G; Cao Z; Han Y; Zhou R
PLoS One; 2015; 10(2):e0118026. PubMed ID: 25689860
[TBL] [Abstract][Full Text] [Related]
4. LAPTM4B Predicts Axillary Lymph Node Metastasis in Breast Cancer and Promotes Breast Cancer Cell Aggressiveness in Vitro.
Xiao M; Yang S; Meng F; Qin Y; Yang Y; Jia S; Cai X; Li C; Huang Y; Ning X
Cell Physiol Biochem; 2017; 41(3):1072-1082. PubMed ID: 28245476
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer.
Xiao M; Jia S; Wang H; Wang J; Huang Y; Li Z
J Cancer Res Clin Oncol; 2013 Apr; 139(4):661-7. PubMed ID: 23292099
[TBL] [Abstract][Full Text] [Related]
6. Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer.
Liu Y; Zhang QY; Qian N; Zhou RL
Ann Oncol; 2007 Feb; 18(2):311-6. PubMed ID: 17074969
[TBL] [Abstract][Full Text] [Related]
7. Beclin1 antagonizes LAPTM4B-mediated EGFR overactivation in gastric cancer cells.
Tian M; Chen Y; Tian D; Qiao X; Ma Z; Li J
Gene; 2017 Aug; 626():48-53. PubMed ID: 28479384
[TBL] [Abstract][Full Text] [Related]
8. Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer.
Meng F; Tan S; Liu T; Song H; Lou G
Tumour Biol; 2016 Apr; 37(4):4849-55. PubMed ID: 26526574
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of LAPTM4B is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer.
Tang H; Tian H; Yue W; Li L; Li S; Gao C; Si L; Qi L; Lu M
Med Oncol; 2014 Jun; 31(6):974. PubMed ID: 24816841
[TBL] [Abstract][Full Text] [Related]
10. Lysosome-associated protein transmembrane-4β-35 is a novel independent prognostic factor in small cell lung cancer.
Qiao M; Hu G
Tumour Biol; 2015 Sep; 36(10):7493-9. PubMed ID: 25910706
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of LAPTM4B and p27kip1 expression in triple-negative breast cancer.
Li X; Song C; Wang K; Li N; Sun S; Li N; Zhao Z; Li M
Cancer Biomark; 2019; 25(1):19-27. PubMed ID: 31033460
[TBL] [Abstract][Full Text] [Related]
12. Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients.
Li S; Wang L; Meng Y; Chang Y; Xu J; Zhang Q
Oncotarget; 2017 Jun; 8(25):41282-41293. PubMed ID: 28476037
[TBL] [Abstract][Full Text] [Related]
13. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.
Yang H; Xiong FX; Lin M; Yang Y; Nie X; Zhou RL
J Cancer Res Clin Oncol; 2010 Feb; 136(2):275-81. PubMed ID: 19690886
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer.
Zhang H; Wei Q; Liu R; Qi S; Liang P; Qi C; Wang A; Sheng B; Li L; Xu Y
PLoS One; 2014; 9(3):e91069. PubMed ID: 24651764
[TBL] [Abstract][Full Text] [Related]
15. Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma.
Peng C; Zhou RL; Shao GZ; Rui JA; Wang SB; Lin M; Zhang S; Gao ZF
World J Gastroenterol; 2005 May; 11(18):2704-8. PubMed ID: 15884107
[TBL] [Abstract][Full Text] [Related]
16. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
17. Identification of Lysosome-Associated Protein Transmembrane-4 as a Novel Therapeutic Target for Osteosarcoma Treatment.
Wang ZX; Guo MY; Ren J; Li GS; Sun XG
Orthop Surg; 2020 Aug; 12(4):1253-1260. PubMed ID: 32558212
[TBL] [Abstract][Full Text] [Related]
18. Elevated lysosome-associated protein transmembrane-4β-35 is an independent prognostic marker in pancreatic carcinoma.
Zhang G; Liang Y; Huang Y; Chen Y; Zhou R
J Int Med Res; 2012; 40(4):1275-83. PubMed ID: 22971479
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of LAPTM4B-35 is a negative prognostic factor in head and neck squamous cell carcinoma.
Kotowski U; Kadletz L; Schneider S; Oberndorfer F; Schnoell J; Gurnhofer E; Kenner L; Lucas T; Heiduschka G
Sci Rep; 2019 Dec; 9(1):18866. PubMed ID: 31827181
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-132-3p inhibits tumor malignant progression by regulating lysosomal-associated protein transmembrane 4 beta in breast cancer.
Li S; Xu JJ; Zhang QY
Cancer Sci; 2019 Oct; 110(10):3098-3109. PubMed ID: 31389121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
